Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC Article Swipe

PDF

Related Concepts

osimertinib t790m medicine oncology epidermal growth factor receptor lung cancer gefitinib internal medicine hazard ratio progression-free survival tyrosine kinase cancer research overall survival cancer erlotinib receptor confidence interval

Suresh S. Ramalingam , Johan Vansteenkiste , David Planchard , Byoung Chul Cho , Jhanelle E. Gray , Yuichiro Ohe , Caicun Zhou , Thanyanan Reungwetwattana , Ying Cheng , Busyamas Chewaskulyong , Riyaz Shah , Manuel Cobo , Ki Hyeong Lee , Parneet Cheema , Marcello Tiseo , Thomas John , Meng‐Chih Lin , Fumio Imamura , Takayasu Kurata , Alexander Todd , Rachel Hodge , Matilde Saggese , Yuri Rukazenkov , Jean‐Charles Soria ·

YOU? · · 2019 · Open Access · · DOI: https://doi.org/10.1056/nejmoa1913662 · OA: W2990041408

Among patients with previously untreated advanced NSCLC with an <i>EGFR</i> mutation, those who received osimertinib had longer overall survival than those who received a comparator EGFR-TKI. The safety profile for osimertinib was similar to that of the comparator EGFR-TKIs, despite a longer duration of exposure in the osimertinib group. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov number, NCT02296125.).